Question Everything. See who's reporting it.

CDSCO approves Leqembi for early Alzheimer's treatment in India

Source: Deccan Herald

The story in brief

The Central Drugs Standard Control Organisation (CDSCO) has approved Eisai’s Leqembi for early Alzheimer’s treatment in India, marking a significant step in managing the disease. The drug, a humanised monoclonal antibody targeting amyloid-beta, requires amyloid pathology confirmation via CSF or serum biomarkers. Eisai plans structured patient support programmes to enhance affordability and access.

NEWXFree on Android and iPhone. Open in NEWX